BioSpace News Archive

Tribun Health, a leading innovator in the field of digital pathology, is delighted to announce the completion of its Series B financing round, securing an investment of €15 million.

Monaghan Medical Corporation and Allergan Sales, LLC have announced a mutual agreement wherein Monaghan will assume the direct management of the AeroChamber® brand Valved Holding Chamber for retail pharmacy markets.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”) today announced that Cary Claiborne, CEO of Adial Pharmaceuticals, will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.

IMUNON, Inc., a clinical-stage biotechnology company, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.

Illumina, Inc. announced that its Board of Directors has appointed Jacob Thaysen, Ph.D., senior vice president of Agilent Technologies and president of its Life Sciences and Applied Markets Group, as Chief Executive Officer, effective September 25, 2023.

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that Chairperson and Chief Executive Officer Al Altomari and Chief Commercial Officer Amy Welsh will present at the H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023 in New York, NY.

KALA BIO, Inc., a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, announced that management will present at the H.C. Wainwright 25th Annual Global Investment Conference, being held virtually and in New York, NY.

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in a fireside chat on Tuesday, September 12, 2023, at 5:30 pm Eastern Time at the Morgan Stanley 21st Annual Global Healthcare Conference.

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today received authorization of its Clinical Trial Application (CTA) by the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 2 trial in Early Alzheimer’s disease (AD) with XPro™.

Foghorn ® Therapeutics Inc. today announced management’s participation in the following investor conferences in September 2023.